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Position Statement
BRONCHIECTASIS is a progressive disease process charac-
terised by dilated, thick-walled bronchi caused by chronic
bacterial or viral infection and inflammation. It is now rarely
encountered in developed countries, except in patients with
cystic fibrosis (CF), or in association with other underlying
causes such as ciliary dyskinesia, immune deficiency or focal
lung abnormalities. In contrast, bronchiectasis remains
common among Indigenous populations, involving 1%–2%
of all children, with symptoms frequently dating back to
infancy.1,2
The burden of ill-health from respiratory disease among
Indigenous Australians is significant.3 Respiratory disease is
the commonest preventable, defined cause of infant deaths,4
the most common disorder in children aged under 5 years in
Northern Territory hospital morbidity data,5 and the sec-
ond-highest cause of death among adults. The true preva-
lence of bronchiectasis and associated respiratory illness in
Indigenous children in Australia is unknown, but is likely to
be disproportionately high in rural and remote communi-
ties. A recently completed central Australian study esti-
mated the rate of bronchiectasis (confirmed by high-
resolution computed tomography [HRCT]6,7) in children
aged under 15 years as 147 per 10 000 Aboriginal children
(unpublished data), a rate 40-fold greater than that for CF
in non-Indigenous populations (35 per 100 000).8 However,
there are no programs or resources to manage these
patients, and even a perception that “nothing can be done”
— similar to the situation that existed for patients with CF
several decades ago.
Consequently, the Working Group on Indigenous Paedi-
atric Respiratory Health developed consensus recommenda-
tions. The consensus process is summarised in Box 1, our
recommendations are listed in Box 2 and research goals in
Box 3. The recommendations were conditioned by the
current incomplete knowledge of the aetiology and disease
mechanisms of bronchiectasis, and a lack of large ran-
domised-controlled trials able to detect clinically significant
differences for interventions in non-CF bronchiectasis.
These limitations were most apparent in children. For these
reasons, the consensus recommendations are based on the
best available evidence, including extrapolation from studies
in CF patients.
Early detection (Box 2, Objective A)
Diagnosis
The clinical case definition of bronchiectasis is imprecise and
its severity and extent is highly variable, ranging from mild
respiratory morbidity to death. Symptoms suggestive of the
disease are listed in Box 2. Chest radiographs are relatively
insensitive, one study detecting fewer than 50% of patients
with bronchography-proven bronchiectasis.6 Peribronchial
fibrosis thickens bronchial walls so that they are seen as
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ABSTRACT
■ The rates of bronchiectasis for Indigenous children from 
remote Australian communities are unacceptably high, 
with one study showing 14.7/1000 Aboriginal children.
■ Children with bronchiectasis need to be identified early 
for optimisation of medical treatment. Under-reporting of 
cough is common. Bronchiectasis should be suspected 
in children with recurrent bronchitis or pneumonia, and 
when, despite appropriate therapy, pulmonary infiltrates 
or atelectasis persist 12 weeks beyond the index illness.
■ During acute infective episodes, oral antibiotics and chest 
physiotherapy to clear the airways should produce prompt 
resolution; otherwise, hospitalisation is necessary.
■ Management follows the cystic fibrosis model of regular 
review, encouragement of physical activity, optimising 
nutrition, maintenance of immunisation and avoidance 
of environmental toxicants, including passive smoke 
exposure.
■ Successful management and prevention of bronchiectasis 
will require improvements in housing, nutrition, and 
education, as well as access to comprehensive healthcare 
services, with coordination between primary and hospital-
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“tramlines”, especially in the lower lobes. HRCT optimised
with a high-spatial-frequency reconstruction algorithm is the
current “gold standard” for identifying bronchiectatic air-
ways.9 Typical HRCT findings of bronchiectasis include
“signet-ring” appearance (dilated bronchus compared with
adjacent pulmonary artery), loss of bronchial tapering, and
end-expiratory scans showing increased translucency in areas
of air trapping from small-airways disease.
Recurrent lower respiratory tract infection
Infection is an important contributor to later respiratory
morbidity, chronic lung disease and pulmonary function
abnormalities.10-18 The nasopharyngeal spaces of Indigenous
central Australian children are heavily colonised by potential
respiratory tract bacterial pathogens,19 and the attack rates of
acute lower respiratory tract infection are similar to those in
children in developing countries.20 Of 116 children aged
under 15 years admitted to Alice Springs Hospital (October
2000 – April 2001) with radiologically defined lobar pneu-
monia, 58 (50%) had previously been hospitalised on two or
more occasions for acute lower respiratory tract infections.
As of June 2001, of 76 children (84 episodes, 64% of
children) reviewed 2–8 months later, 10 (13%) were diag-
nosed with bronchiectasis by HRCT in the non-acute state
(unpublished data). Given the high rate of respiratory mor-
bidity after hospitalisation in this patient group, clinical
follow-up is recommended as a minimum (C1).
Investigations
The principal aims of investigations in children with sus-
pected bronchiectasis are to confirm the diagnosis, to define
the distribution and severity of airway involvement, and to
identify familial and treatable causes of bronchiectasis.
Chest HRCT should identify congenital lesions and deter-
mine the extent and severity of disease. Lung function tests
are non-specific, but in older children provide a measure of
functional impairment and small-airways involvement.18
Other investigations include sputum culture for bacteria and
mycobacterial species, sweat testing (although CF is
extremely rare in Aboriginal children), Mantoux testing,
immune function assessment (differential white-cell count,
HIV, immunoglobulins G, A, M, E and IgG subclasses,
antibody responses to protein and polysaccharide antigens)
and nasal cilia biopsy (C2) (although transient abnormal
cilia are often found with nasal space disease, which is a very
common occurrence in rural Indigenous children).20 For
selected patients, bronchoscopy to exclude a foreign body
and obstructive bronchiectasis, as well as fluoroscopic
1: Consensus process
The working group comprised 44 representatives from Australian 
and New Zealand medical schools, secondary and tertiary 
paediatric centres (see Acknowledgements). Collectively, the group 
possessed expertise in Indigenous health, paediatric and 
respiratory medicine, microbiology, infectious diseases and public 
health. MEDLINE databases were searched from January 1966 to 
November 2001 for subject headings (bronchiectasis, bronchitis, 
suppurative lung, suppurative respiratory disease) and the 
Cochrane database was also accessed using these headings. 
Review of references led to identification of relevant articles 
published before 1966, while experts in the working group identified 
unpublished data. The first draft of the working group's consensus 
statement followed a two-day meeting in Alice Springs in August 
2001, where the available evidence was presented and reviewed. 
Suggested revisions were incorporated into subsequent drafts, so 
that the final draft represents all relevant evidence obtained by the 
literature search, in conjunction with final consensus 
recommendations annotated to reflect the level of consensus 
among the entire group.
E1: Systematic review of all relevant randomised-controlled trials 
(RCTs)
E2: Well-designed RCTs
E3: Well-designed cohort or case–control studies
C1: Complete consensus of entire working group
C2: Near-complete consensus (95% or more of working group)
C3: No consensus
2: Recommendations
Objective A: To encourage early diagnosis of bronchiectasis
■ Bronchiectasis should be suspected in any child with recurrent 
lower respiratory tract infection, prolonged moist-sounding 
cough, exertional dyspnoea, symptoms of reactive airways 
disease, growth failure, hyperinflation of lungs, chest deformity or 
digital clubbing (E3). Under-reporting of cough is common and 
obtaining additional medical information from the local community 
(clinic staff, notes, carers, health workers) is important (C1).
■ For prompt detection of bronchiectasis, all Indigenous children 
with radiologically proven pneumonia should undergo clinical 
review (C1). If the child is aged < 2 years, has a history of 
recurrent bronchitis or pneumonia, atelectasis is present in the 
initial radiograph, or a chronic cough (> 4–6 weeks) is suspected, 
a chest radiograph is performed 6–8 weeks after treatment to 
ensure complete radiological resolution (C2).
■ When, despite treatment, radiological changes persist for more 
than 3 months, or when symptoms and/or signs suggest the 
presence of bronchiectasis, chest high-resolution computed 
tomography scans should be performed in the non-acute state 
(C1).
Objective B: To optimise medical management to reduce morbidity 
and preserve lung function
■ Management following CF models of care is recommended (C2). 
Exacerbations are treated with antibiotics determined by sputum 
bacteriology (E3). Treatment duration of 2–6 weeks is defined by 
the child’s general health, the amount of sputum and the 
pathogen cultured (E3). When respiratory secretion collection is 
not possible, empirical antibiotic therapy is directed at pathogens 
commonly associated with bronchiectasis (C2).
■ Children with bronchiectasis should be reviewed 3-monthly by the 
most appropriate local doctor, in consultation with other 
healthcare providers, and have a minimum 6-monthly review by a 
paediatrician or respiratory physician (C2).
■ Immunisation status should be reviewed and updated (C1).
Objective C: To promote public health issues and healthcare 
delivery
■ Exposure to wood smoke and environmental tobacco smoke 
should be minimised (E3).
■ A culture- and expertise-appropriate healthcare delivery model 
and a coordinated approach among various healthcare providers 
should be used (C1).
■ The socioeconomic determinants of health must be recognised 
(C1).
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examination for aspiration, are recommended (C1). The
extent of investigations has to be considered on an individ-
ual basis for children from remote communities (C1).
Management (Box 2, Objective B)
Without adequate data to guide management of non-CF
bronchiectasis, a similar approach to the management of
CF21,22 (and ciliary dyskinesia23) is recommended (C2).
However, it is uncertain whether CF patients, with their
multiorgan involvement, exaggerated airway inflammatory
responses and accelerated disease progression, serve as the
best model of care for those with bronchiectasis from other
aetiologies. In addition, the respiratory pathogens involved
only partially overlap.21
Management of bronchiectasis involves aggressive treat-
ment of recurrent exacerbation, promotion of mucociliary
clearance (chest physiotherapy, exercise, etc), a vigilant
approach to reduce lung damage from other causes (eg,
aspiration), promotion of normal growth, management of
psychosocial aspects, and identification and treatment of
complications as they arise.21,24 Other aspects include regu-
lar review, optimising nutrition, maintenance of immunisa-
tion and avoidance of environmental toxicants, including
passive smoke exposure.
Treatment of infection
Mechanism of bronchial injury
It is hypothesised that, in some children, impaired mucocili-
ary clearance after severe or recurrent acute lower respira-
tory tract infection allows development of endobronchial
infection by microaspiration of nasopharyngeal bacteria,25
inflammation and progressive bronchial wall injury. Recur-
rent inflammation may impair lung growth as well as
accelerate respiratory function decline.26,27
Infective organisms
There are no published data on organisms that colonise and
cause exacerbations in Indigenous Australian children with
bronchiectasis. Haemophilus influenzae, Streptococcus pneu-
moniae and Moraxella catarrhalis, bacteria that colonise the
nasopharynx, cause lower respiratory tract infections and
are associated with bronchiectasis in other Indigenous pop-
ulations.2,19 Unlike in CF,28 Staphylococcus aureus is uncom-
mon, and opportunistic pathogens like Pseudomonas
aeruginosa are usually only found in the sputum of older
patients with advanced disease.29,30 Sputum cultures may be
contaminated by upper-airway organisms and antibiotics
should be directed against anticipated pathogens. More
invasive testing, for example by induced sputum or bron-
chial lavage, should be considered if symptoms persist (C2).
Antibiotic therapy
When bronchiectasis is mild, antibiotics may eradicate the
infection, and lung defences keep the airways sterile or
bacterial numbers low for prolonged periods.31 If airway
injury is more severe, the bronchi are chronically infected
and symptoms may rapidly return. However, apart from
studies on chronic P. aeruginosa infection in adults with CF,
there are no studies to show that long-term antibiotics
prevent disease progression.32 It is for this reason, and the
risk of selecting resistant organisms, that interval rather than
suppressive antibiotic therapy is recommended (C1).
Children with a chronic moist-sounding cough should
receive antibiotics such as amoxycillin–clavulanate (or high
dose amoxycillin, co-trimoxazole, cefaclor) for 2–6 weeks or
until the cough resolves (C1). If the cough does not
improve, the patient requires specialist reassessment or
hospitalisation, particularly if there is a deterioration in
general health, weight loss, reduced lung function or new
radiographic infiltrates (C2). Inpatient management
includes parenteral antibiotics, such as ampicillin, cefotax-
ime or ceftriaxone, and intensive physiotherapy (C1). When
P. aeruginosa is present, ciprofloxacin or combined therapy
with an antipseudomonal -lactam and an aminoglycoside is
preferred (C1). Given the lack of resources in their commu-
nities, Indigenous children with moderate or severe bron-
chiectasis are more likely to require hospitalisation (C2).
Antibiotics in adults with bronchiectasis significantly
improve quality-of-life measures,30,33 and airway and
systemic33 inflammatory profiles.33,34 Similar information in
children is lacking, and there are no data evaluating the
effects of long-term antibiotics on acquisition of antibiotic-
resistant pathogens.
Other measures
Reactive airways disease can be present in children with
bronchiectasis,35 and the use of asthma medications should
3: Research goals
Aetiology and disease burden
■ Identify the respiratory disease burden
■ Describe aetiological and modifiable risk factors
■ Determine whether acute lower respiratory tract infection is 
adequately treated, with resolution of symptoms and pulmonary 
infiltrates
■ Pursue the relationship between genes, polymorphisms and 
regulation of the immune response
■ Determine the relationship between chronic ear disease and 
bronchiectasis, and whether nasopharyngeal colonisation by 
potential respiratory pathogens is a risk factor
■ Distinguish whether early and aggressive treatment of pre-
bronchiectatic chronic suppurative lung disease can prevent the 
development of bronchiectasis
Management
■ Identify the predominant pathogens and determine the best 
means of collecting respiratory secretions from non-expectorating 
patients
■ Conduct intervention studies to determine the type and duration 
of antibiotic therapy, stratified by disease severity
■ Conduct intervention studies to determine the role of antibiotic 
suppressive therapy
■ Describe the role and best method of chest physiotherapy
■ Determine the best outcome measures for young children
■ Resolve whether early management preserves lung function
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be individualised (C1). There are insufficient data to recom-
mend the regular use of inhaled or oral corticosteroids,36 2-
agonists, mucolytics or methylxanthines in patients with
bronchiectasis.
Chest physiotherapy
Chest physiotherapy improves airway clearance, but the best
method is yet to be defined. Although there are no control-
led trials on the role of surgery, it may be considered in
those who have passed puberty when bronchiectasis is focal
and medical therapy has failed37 (C1).
Regular review
Regular review aims to optimise lung growth, minimise
respiratory decline, improve quality of life and provide
health education (C1). The review should include measure-
ment of pulmonary function (for children aged 6 years or
over), assessment and management of pulmonary deteriora-
tion and infective exacerbations (sputum and cough
changes, exertional dyspnoea), management of complica-
tions of bronchiectasis (pulmonary hypertension, chronic
hypoxaemia, poor growth, sleep disturbance, reactive air-
ways disease, haemoptysis) and a review of contributory
factors (eg, gastro-oesophageal reflux, asthma, environmen-
tal smoke exposure). As with successful CF models,21,22 a
multidisciplinary approach with nursing and allied health
expertise (social work, physiotherapy, dietitian) is used.38
This requires appropriate health resources and adequate
systems that support specific management plans for children
and carers (C2). An individualised management protocol is
important, with a leader selected from the team to take
responsibility for each child (C2).
Vaccination
Immunisation programs should include vaccination against
pneumococcus and influenza, in addition to the routine
childhood vaccination schedule (C1). Future vaccine devel-
opment may allow the introduction of vaccines that protect
against non-type b and non-typable strains of H. influenzae,
M. catarrhalis and respiratory syncytial virus.
Public health issues and healthcare delivery 
(Box 2, Objective C)
These extremely important topics cannot be adequately
covered in this article. In brief, health is closely linked to
socioeconomic factors.39 Successful management and pre-
vention of bronchiectasis among Indigenous populations
will only be achieved by delivering comprehensive health-
care, accompanied by improvements in housing, nutrition
and education, and by alleviation of poverty and unemploy-
ment (C1).
The effects of in-utero and ex-utero exposure to environ-
mental tobacco smoke on children’s respiratory system
include reduced lung function, increased acute lower respi-
ratory tract infection, and middle-ear disease40 (E3). Indoor
wood smoke increases acute lower respiratory tract infec-
tion, demonstrating an exposure–response effect41 (E3).
Interventions to reduce environmental tobacco smoke and
biomass smoke exposure are urgently needed. The associa-
tion between maternal education and childhood health
indices in developing nations42 has not been shown to occur
in the Australian Indigenous population. An increased risk
of acute lower respiratory tract infection is associated with
greater numbers of house occupants, damp housing, macro-
and micromalnutrition, and inadequate water supply43,44
(E3).
No single model of healthcare delivery can be used for all
Indigenous communities. A comprehensive and competent
primary healthcare service is a prerequisite for the effective
delivery of any treatment and disease control program.
Education of primary healthcare providers to identify appro-
priate children for referral and primary management of
children with bronchiectasis would be beneficial (C2).
The challenge for health service systems is to find ways to
deliver effective, competent and quality healthcare despite
problems that include remoteness, endemic poverty, severe
educational disadvantage, dysfunctional communities, and
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